Expert Opinion on Drug Safety

The multiple faces of quercetin in neuroprotection
pp. 397-409(13)
Authors: Ossola, Bernardino; Kääriäinen, Tiina M; Männistö, Pekka T

Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use
pp. 411-419(9)
Authors: Cook, Aaron M; Whitlow, Justin; Hatton, Jimmi; Young, Byron

Considerations in sirolimus use in the early and late post-transplant periods
pp. 421-434(14)
Authors: Patel, Samir J; Elliott, Erin N; Knight, Richard J; Gaber, Lillian W; Gaber, A Osama

Inhaled therapeutics for prevention and treatment of pneumonia
pp. 435-449(15)
Authors: Safdar, Amar; Shelburne, Samuel A; Evans, Scott E; Dickey, Burton F

Mechanisms underlying methotrexate-induced pulmonary toxicity
pp. 451-458(8)
Authors: Kim, Youn-Jung; Song, Mee; Ryu, Jae-Chun

Type I IFNs and their role in the development of autoimmune diseases
pp. 459-472(14)
Authors: Burdick, Laura M; Somani, Najwa; Somani, Ally-Khan

Occupational exposure to anaesthetic gases: a role for TIVA
pp. 473-483(11)
Authors: Irwin, Michael G; Trinh, Theresa; Yao, Che-Lin

Update on the safety of linezolid
pp. 485-491(7)
Authors: Metaxas, Eugenios I; Falagas, Matthew E

The safety of temozolomide in the treatment of malignancies
pp. 493-499(7)
Authors: Trinh, Van Anh; Patel, Sapna Pradyuman; Hwu, Wen-Jen

Long-term safety of tacrolimus ointment in atopic dermatitis
pp. 501-506(6)
Authors: Remitz, Anita; Reitamo, Sakari